Business
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Research at the 2016 AACR Annual Meeting
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Research at...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Research at the 2016 AACR Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Research at the 2016 AACR Annual Meeting\nCanada NewsWire\nCALGARY, April 18, 2016\n\n\n\nCALGARY, April 18, 2016 /CNW/ - Oncolytics Biotech® Inc. (\"Oncolytics\" or the \"Company\") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced that two poster presentations covering preclinical work in multiple myeloma and colorectal cancer are being made by the Company's research collaborators at the 2016 American Association of Cancer Research annual meeting being held from April 16th to 20th, 2016 in New Orleans, LA.\n\n\"Both multiple myeloma and colorectal cancer are target indications for later-stage clinical testing of REOLYSIN®,\" said Dr. Brad Thompson, President and CEO of Oncolytics. \"These important preclinical findings continue to advance our understanding of how REOLYSIN® interacts with the immune system and how immunomodulatory interventions could improve its cancer cell killing capabilities.\"\n\nThe first abstract/poster is titled \"Successful oncolytic virotherapy in a bortezomib resistant syngeneic mouse model of multiple myeloma: implications for translation significance,\" and was authored by Thirukkuamaran, et al. Using the VK*MYC bortezomib resistant transplantable multiple myeloma mouse model, the authors demonstrated that mice harboring bortezomib insensitive multiple myeloma tumors significantly responded to reovirus treatment. These data are supportive of previous and ongoing preclinical and clinical work in this indication and the Company is currently enrolling patients in a Phase 1b study of REOLYSIN® in combination with bortezomib in patients with relapsed or refractory multiple myeloma.\n\nThe second abstract/poster is titled \"Toll like receptor 3 as an immunotherapeutic target for Kras mutated colorectal cancer,\" and was authored by Goel, et al. The authors hypothesized that ...